Loss of micro-RNA may trigger malignant growth in lung cancer cells

Share this article:


Micro-RNA plays an important role in the malignancy of lung cancer, according to a study published in Molecular Cancer Research (2010 Sep;8(9):1207-16).

Led by Heike Allgayer, medical researcher and head of a clinical cooperation unit of DKFZ and UMM, a team of researchers studied various cell lines of non-small cell lung cancer to investigate miR-200c and its role in malignant growth. They discovered that the less miR-200c is produced by a cell line, the higher its motility and its capacity to invade surrounding tissue. Furthermore, when the researchers experimentally equipped the cancer cells with additional miR-200c, the amount of tissue-anchoring molecules on their surface increased and their invasive capacity became lower.

Dr. Allgayer's team also reported that in the highly aggressive cells, the miR-200c genes were turned off by a chemical labeling with methyl groups, and drugs that removed the labels made the production of miR-200c rise again.

When researchers studied the tumor cells of 69 lung cancer patients, they determined miR-200c levels and compared them with the patients' disease progression data. They found that the lower the miR-200c level in the cancer cells, the more frequently metastasis had already begun.

“Our results clearly show a connection between a loss of miR-200c and transition to aggressive, invasive growth, metastasis, and chemoresistance,” concluded Dr. Allgayer. “Therefore, we will now investigate whether miR-200c production in cancer cells can be used for predicting metastasis and, thus, may serve as a prognosis factor for the progression of a lung cancer. It is also possible that the miR-200c level can help to better predict the effectiveness of particular drugs.”

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.